Trial · NCT05384847
Effects of Triiodothyronine (T3) in Ischemic Heart Failure
NCT05384847, Phase 1, Completed, Emory University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Triiodothyronine (T3) in Ischemic Heart Failure. Trials, record NCT05384847. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05384847
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Triiodothyronine (T3) in Ischemic Heart Failure
- NCT number
- NCT05384847
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 14 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Heart Failure
- Interventions
- Thyroid hormone T3, Control Group
- First posted
- 2022-05-20
- Last updated
- 2026-08-04
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in the presence of clinical arrhythmias | Baseline, Days 1*, 2*, 3*, 4*, 5*, 6 weeks, 3 months, 6 months, 12 months | An electrocardiogram will be performed during each study visit and the presence of any Clinical arrhythmias such as ectopy, atrial fibrillation, ventricular arrhythmias, ICD firing will be documented. \*Days 1 through 5 apply only to those who are admitted to the GCRC unit. |
| Primary | The number of participants with Angina, acute coronary syndrome, death during the first week | During the first week of treatment period | The total number of subject's events during the first week of the treatment period will be recorded |
| Secondary | Change in left ventricular ejection fraction (LVEF) | Baseline, Day 45, Day 90 | An echocardiogram will be performed at specific study visits and LVEF will be measured |
| Secondary | Change in 6-minute walk distance (6MWD) | Baseline, Day 45, Day 90 | Two 6-minute walk tests will be completed at least 2 hours apart to establish a baseline. The mean of the 2 distances will be used as the baseline. The six-minute walk test requires a 100-ft hallway. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The six-minute walk test serves as a standardized test for functional capacity quantification of HF patients and is predictive of adverse cardiovascular outcomes. Most patients do not achieve maximal exercise capacity during the 6-minute walk test; instead, they choose their own intensity of exercise and can stop and rest during the test. |
| Secondary | Changes in New York Heart Association (NYHA) classification | Baseline, Day 45, Day 90 | Participants will be asked about exertional symptoms for NYHA functional categorization of HF symptoms at all time points. Symptom-based scores range from I to IV. The NYHA classification system also includes an objective assessment of cardiovascular disease severity, which ranges from A-D. Differences between treatment and control arms over time will be analyzed as well as within arms over time. |
| Secondary | Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) | Baseline, Day 45, Day 90 | This is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and quality of life limitation due to HF. Scores range from 0 to 100. For the KCCQ overall summary score, a small but clinically meaningful change is ≥ 5 points. |
| Secondary | Changes in Brain natriuretic peptide (BNP) levels | Baseline, Day 45, Day 90 | -B-type natriuretic peptide (BNP) will be measured at specific study visits. Differences between treatment and control arms over time will be analyzed as well as within arms over time. |
| Other | Changes in the Left ventricular end-systolic volume (LVESV) and Left ventricular end-diastolic volume (LVEDV) | Baseline, Day 45, Day 90 | An echocardiogram will be performed at specific study visits and LVESV and LVEDV will be measured. |
| Other | Changes Left ventricular end-systolic volume index (LVESVI) and end-diastolic volume index (LVEDVI) | Baseline, Day 45, Day 90 | An echocardiogram will be performed at specific study visits and LVESVI and LVEDVI will be measured. |
| Other | Changes in the LV posterior wall (LVPW) thickness by speckle-tracking echocardiography | Baseline, Day 45, Day 90 | An echocardiogram will be performed at specific study visits where the LV posterior wall (LVPW) thickness by 2D echocardiography (longitudinal and circumferential strain and strain rate). |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41633443 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05384847
GET https://conductscience.org/api/trials/v1/NCT05384847/registered